In addition to mitochondria-targeted antioxidant therapy, our results suggest a number of potential therapeutic options for autoimmune uveitis, including blockade of TNF-α/IL-6 and PAF signaling, inhibition of prostaglandin synthesis or DHA and ascorbic acid supplementation. The gene discussed is PCLAF; the disease is autoimmune uveitis.